This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
To the Editor.—
The recent report of Bayles in the Archives (104:476-485, 1971), concerning the treatment of chromomycosis with thiabendazole, has renewed our interest in the therapeutic approach to this mycosis. Although thiabendazole has been shown to be active in vitro against the etiologic fungi of chromomycosis, the results from the approximately 50 cases treated orally or topically with this agent (alone or with dimethyl sulfoxide [DMSO]) have been equivocal. In the last Ibero-Latin-American Dermatology Meeting (Caracas, Venezuela, Dec 12-16, 1971), Solano reported a thiabendazole trial series with a 30% positive therapeutic response, a 30% moderate response, and a 40% negative therapeutic response. He did suggest, however, that better results might be obtained if the drug had better access to the causative fungus.In 1968, while working with Dr. Alice Parreiras in the Department of Dermatology of Das Clinicas Hospital (S.A.P. Sampaio, Chairman), in São Paulo, Brazil, we used the
Hernandez-Perez E. Treatment of Chromomycosis. Arch Dermatol. 1972;106(1):130. doi:10.1001/archderm.1972.01620100104037
Artificial Intelligence Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.